Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

SIMPLE SUMMARY: Currently available biomarkers for response to checkpoint inhibitors are incomplete and predominantly focus on tumor tissue analysis e.g., tumor mutational burden, programmed cell death-ligand 1 (PD-L1) expression. Biomarkers in peripheral blood would allow a more dynamic monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Meireson, Annabel, Tavernier, Simon J., Van Gassen, Sofie, Sundahl, Nora, Demeyer, Annelies, Spaas, Mathieu, Kruse, Vibeke, Ferdinande, Liesbeth, Van Dorpe, Jo, Hennart, Benjamin, Allorge, Delphine, Haerynck, Filomeen, Decaestecker, Karel, Rottey, Sylvie, Saeys, Yvan, Ost, Piet, Brochez, Lieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198315/
https://www.ncbi.nlm.nih.gov/pubmed/34071888
http://dx.doi.org/10.3390/cancers13112630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198315/
https://www.ncbi.nlm.nih.gov/pubmed/34071888
http://dx.doi.org/10.3390/cancers13112630

Ejemplares similares